Hematopoietic stem cell transplantation for severe combined immunodeficiency in the neonatal period leads to superior thymic output and improved survival
Top Cited Papers
Open Access
- 1 February 2002
- journal article
- Published by American Society of Hematology in Blood
- Vol. 99 (3) , 872-878
- https://doi.org/10.1182/blood.v99.3.872
Abstract
All genetic types of severe combined immunodeficiency (SCID) can be cured by stem cell transplantation from related donors. The survival rate approaches 80%, and most deaths result from opportunistic infections acquired before transplantation. It was hypothesized that the survival rate and kinetics of immune reconstitution would be improved for infants receiving transplants in the neonatal period (first 28 days of life), prior to the development of infections. A 19.2-year retrospective/prospective analysis compared immune function in 21 SCID infants receiving transplants in the neonatal period with that in 70 SCID infants receiving transplants later. Lymphocyte phenotypes, proliferative responses to mitogens, immunoglobulin levels, and T-cell antigen receptor excision circles (TRECs) were measured before transplantation and sequentially after transplantation. Of 21 SCID infants with transplantations in the neonatal period, 20 (95%) survive. Neonates were lymphopenic at birth (1118 ± 128 lymphocytes per cubic millimeter). Infants receiving transplants early developed higher lymphocyte responses to phytohemagglutinin and higher numbers of CD3+ and CD45RA+ T cells in the first 3 years of life than those receiving transplants late (P < .05). TRECs peaked earlier and with higher values (P < .01) in the neonatal transplantations (181 days to 1 year) than in the late transplantations (1 to 3 years). SCID recipients of allogeneic, related hematopoietic stem cells in the neonatal period had higher levels of T-cell reconstitution and thymic output and a higher survival rate than those receiving transplants after 28 days of life. An improved outcome for this otherwise fatal syndrome could be achieved with newborn screening for lymphopenia so that transplantation could be performed under favorable thymopoietic conditions.Keywords
This publication has 21 references indexed in Scilit:
- Thymic Function after Hematopoietic Stem-Cell Transplantation for the Treatment of Severe Combined ImmunodeficiencyNew England Journal of Medicine, 2000
- Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 DiseaseScience, 2000
- A new gene involved in DNA double-strand break repair and V(D)J recombination is located on human chromosome 10pHuman Molecular Genetics, 2000
- Hematopoietic Stem-Cell Transplantation for the Treatment of Severe Combined ImmunodeficiencyNew England Journal of Medicine, 1999
- Human severe combined immunodeficiency: Genetic, phenotypic, and functional diversity in one hundred eight infantsThe Journal of Pediatrics, 1997
- RAG Mutations in Human B Cell-Negative SCIDScience, 1996
- Mutation of Jak3 in a Patient with SCID: Essential Role of Jak3 in Lymphoid DevelopmentScience, 1995
- Severe combined immunodeficiency: A retrospective single-center study of clinical presentation and outcome in 117 patientsThe Journal of Pediatrics, 1993
- The interleukin-2 receptor γ chain maps to Xq13.1 and is mutated in X-linked severe combined immunodeficiency, SCIDX1Human Molecular Genetics, 1993
- Interleukin-2 receptor γ chain mutation results in X-linked severe combined immunodeficiency in humansCell, 1993